Latest Health News

InVert Graphite has completed its maiden drilling program at the Kumba deposit in Tanzania, revealing wide zones of high-grade graphite near surface and positioning the Morogoro Project for further advancement.

Pantoro Gold delivered a solid December quarter with strong gold production, robust EBITDA, and promising exploration results at its Norseman Gold Project.

Spheria Emerging Companies Limited announces a fully franked 3.8 cents per share quarterly dividend for December 2025 and initiates monthly dividends of 1.3 cents for February and March 2026 as it transitions dividend payments from quarterly to monthly.

Imricor Medical Systems has secured Virginia Commonwealth University Health as the third US site for its VISABL-AFL clinical trial, advancing its FDA approval pathway for MRI-guided cardiac ablation technology.

OMG Group Limited has reported its first positive operating cashflow quarter, driven by a 63% year-on-year sales increase and expansion into premium Japanese matcha wholesale. This milestone signals a turning point in the company’s growth trajectory.

BCAL Diagnostics has launched its Avantect pancreatic and ovarian cancer tests in Australia, alongside expanding clinical data and establishing a national registry for its BREASTESTplus breast cancer test.

Vulcan Energy has reported strong production test results from its LSC-1b sidetrack well, reinforcing the viability of its Phase One Lionheart lithium project in Germany. The well’s performance supports the project’s ambitious lithium and renewable energy production targets.

Anteris Technologies has launched a $200 million public offering alongside a $90 million strategic investment from Medtronic, aiming to accelerate its DurAVR heart valve clinical trials and manufacturing expansion.

Audeara Ltd reported a strong Q2 FY26 with revenues up 274% year-on-year, securing key regulatory approval in China and expanding its global licensing footprint.

Atomo Diagnostics has locked in exclusive global rights to a novel liver function test that rapidly detects liver injury, expanding its footprint in point-of-care diagnostics. The test, delivered on Atomo’s Pascal platform, targets drug-induced liver injury and chronic liver conditions with significant commercial potential.

Qoria Limited has reported a record-breaking quarter with annual recurring revenue exceeding US$100 million and a 42% increase in net ARR for Q2 FY2026, reaffirming its strong growth trajectory and FY26 guidance.

Genetic Signatures reported a $3.3 million quarterly revenue with growing international sales and a robust cash position, while preparing for a leadership change.